Author/Authors :
Ochiai، نويسنده , , K. and Yoshikawa، نويسنده , , Y. and Oonuma، نويسنده , , T. and Tomioka، نويسنده , , Y. and Hashizume، نويسنده , , K. and Morimatsu، نويسنده , , M.، نويسنده ,
Abstract :
In humans, mutations in the gene for the breast cancer susceptibility protein BRCA2 affect its interactions with the recombinase RAD51 and are associated with an increased risk of cancer. This interaction occurs through a series of eight BRC repeat sequences in BRCA2. A mammalian two-hybrid assay using individual BRC repeats demonstrated that BRC6 did not bind to RAD51, whereas there was strong (BRC1, 2 and 4), intermediate (BRC8), or weak (BRC3, 5 and 7) binding of other BRC repeats to RAD51. In serial deletion mutation experiments, binding strengths were increased when the C-terminal BRC repeat was removed from BRC1–8, BRC1–5 and BRC1–3. These results may provide an insight into the effects of missense or truncation mutations in BRCA2 in canine tumours.